Summary of publications describing the impact of HU on ACS in patients with sickle cell disease
Follow-up times are given as mean or median as reported by each study. pt-y indicates patient-years; Hgb, hemoglobin, IRR, incidence rate ratio; and HR, hazard ratio.
*Secondary analysis.
†Publication described as a nonrandomized trial, but those on HU were not compared with patients not on HU (ie, no control group comparisons were reported).